Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NWRD06 in GPC3-positive HCC after resection
NCT07324304Phase 2Recruiting
- Sponsor
- Newish Technology (Beijing) Co., Ltd.
- Start
- Dec 2025
- Primary completion
- Dec 2028
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of NWRD06 in hepatocellular carcinoma (HCC), sponsored by Newish Technology (Beijing) Co., Ltd.. Started Dec 2025; status: recruiting.
02
Drugs
NWRD06
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07324304.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07324304.